<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34685754</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>30</Day></DateCompleted><DateRevised><Year>2021</Year><Month>11</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2073-4409</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>10</Issue><PubDate><Year>2021</Year><Month>Oct</Month><Day>16</Day></PubDate></JournalIssue><Title>Cells</Title><ISOAbbreviation>Cells</ISOAbbreviation></Journal><ArticleTitle>Coactivation of GSK3&#x3b2; and IGF-1 Attenuates Amyotrophic Lateral Sclerosis Nerve Fiber Cytopathies in SOD1 Mutant Patient-Derived Motor Neurons.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2773</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/cells10102773</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a progressive nervous system disease that causes motor neuron (MN) degeneration and results in patient death within a few years. To recapitulate the cytopathies of ALS patients' MNs, <i>SOD1</i><sup>G85R</sup> mutant and corrected <i>SOD1</i><sup>G85G</sup> isogenic-induced pluripotent stem cell (iPSC) lines were established. Two <i>SOD1</i> mutant ALS (<i>SOD1<sup>G85R</sup></i> and <i>SOD1</i><sup>D90A</sup>), two <i>SOD1</i> mutant corrected (<i>SOD1</i><sup>G85G</sup> and <i>SOD1</i><sup>D90D</sup>), and one sporadic ALS iPSC lines were directed toward MNs. After receiving ~90% purity for MNs, we first demonstrated that <i>SOD1</i><sup>G85R</sup> mutant ALS MNs recapitulated ALS-specific nerve fiber aggregates, similar to <i>SOD1</i><sup>D90A</sup> ALS MNs in a previous study. Moreover, we found that both <i>SOD1</i> mutant MNs showed ALS-specific neurite degenerations and neurotransmitter-induced calcium hyperresponsiveness. In a small compound test using these MNs, we demonstrated that gastrodin, a major ingredient of <i>Gastrodia elata</i>, showed therapeutic effects that decreased nerve fiber cytopathies and reverse neurotransmitter-induced hyperresponsiveness. The therapeutic effects of gastrodin applied not only to <i>SOD1</i> ALS MNs but also to sporadic ALS MNs and <i>SOD1</i><sup>G93A</sup> ALS mice. Moreover, we found that coactivation of the GSK3&#x3b2; and IGF-1 pathways was a mechanism involved in the therapeutic effects of gastrodin. Thus, the coordination of compounds that activate these two mechanisms could reduce nerve fiber cytopathies in <i>SOD1</i> ALS MNs. Interestingly, the therapeutic role of GSK3&#x3b2; activation on <i>SOD1</i> ALS MNs in the present study was in contrast to the role previously reported in research using cell line- or transgenic animal-based models. In conclusion, we identified in vitro ALS-specific nerve fiber and neurofunctional markers in MNs, which will be useful for drug screening, and we used an iPSC-based model to reveal novel therapeutic mechanisms (including GSK3&#x3b2; and IGF-1 activation) that may serve as potential targets for ALS therapy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ting</LastName><ForeName>Hsiao-Chien</ForeName><Initials>HC</Initials><AffiliationInfo><Affiliation>Bioinnovation Center, Buddhist Tzu Chi Medical Foundation, Hualien 97002, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Hui-I</ForeName><Initials>HI</Initials><AffiliationInfo><Affiliation>Bioinnovation Center, Buddhist Tzu Chi Medical Foundation, Hualien 97002, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Medical Sciences, Tzu Chi University, Hualien 97004, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harn</LastName><ForeName>Horng-Jyh</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Bioinnovation Center, Buddhist Tzu Chi Medical Foundation, Hualien 97002, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, Hualien Tzu Chi Hospital and Tzu Chi University, Hualien 97002, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiu</LastName><ForeName>Ing-Ming</ForeName><Initials>IM</Initials><Identifier Source="ORCID">0000-0001-6512-9815</Identifier><AffiliationInfo><Affiliation>Institute of Cellular and System Medicine, National Health Research Institutes, Miaoli 35053, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Hong-Lin</ForeName><Initials>HL</Initials><AffiliationInfo><Affiliation>Department of Life Sciences, National Chung Hsing University, Taichung 40227, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xiang</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Waisman Center, University of Wisconsin, Madison, WI 53705, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Mei-Fang</ForeName><Initials>MF</Initials><AffiliationInfo><Affiliation>Department of Medical Research, Hualien Tzu Chi Hospital, Hualien 97002, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ho</LastName><ForeName>Tsung-Jung</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Institute of Medical Sciences, Tzu Chi University, Hualien 97004, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Chinese Medicine, Hualien Tzu Chi Hospital, Hualien 97002, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Integration Center of Traditional Chinese and Modern Medicine, Hualien Tzu Chi Hospital, Hualien 97002, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Post-Baccalaureate Chinese Medicine, Tzu Chi University, Hualien 97004, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Ching-Ann</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Bioinnovation Center, Buddhist Tzu Chi Medical Foundation, Hualien 97002, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Research, Hualien Tzu Chi Hospital, Hualien 97002, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Center, Hualien Tzu Chi Hospital, Hualien 97002, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>Yung-Jen</ForeName><Initials>YJ</Initials><AffiliationInfo><Affiliation>Bioinnovation Center, Buddhist Tzu Chi Medical Foundation, Hualien 97002, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiou</LastName><ForeName>Tzyy-Wen</ForeName><Initials>TW</Initials><AffiliationInfo><Affiliation>Department of Life Science, National Dong Hwa University, Hualien 97441, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Shinn-Zong</ForeName><Initials>SZ</Initials><AffiliationInfo><Affiliation>Bioinnovation Center, Buddhist Tzu Chi Medical Foundation, Hualien 97002, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Medical Sciences, Tzu Chi University, Hualien 97004, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosurgery, Hualien Tzu Chi Hospital, Hualien 97002, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Chia-Yu</ForeName><Initials>CY</Initials><Identifier Source="ORCID">0000-0002-3585-5944</Identifier><AffiliationInfo><Affiliation>Bioinnovation Center, Buddhist Tzu Chi Medical Foundation, Hualien 97002, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Research, Hualien Tzu Chi Hospital, Hualien 97002, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Center, Hualien Tzu Chi Hospital, Hualien 97002, Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>TC-NHRI106-01 and IMAR-110-01-02</GrantID><Agency>Hualien Tzu Chi Hospital</Agency><Country/></Grant><Grant><GrantID>MOST 107-2314-B-303-001-, MOST 108-2314-B-303-009-, MOST 109-2314-B-303-023-, MOST 110-2314-B-303-025- and MOST 110-2314-B-303 -017 -MY3</GrantID><Agency>Ministry of Science and Technology</Agency><Country/></Grant><Grant><GrantID>MF00A130SS01</GrantID><Agency>Buddhist Tzu Chi Medical Foundation</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>10</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Cells</MedlineTA><NlmUniqueID>101600052</NlmUniqueID><ISSNLinking>2073-4409</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001592">Benzyl Alcohols</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005960">Glucosides</NameOfSubstance></Chemical><Chemical><RegistryNumber>3KX376GY7L</RegistryNumber><NameOfSubstance UI="D018698">Glutamic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>5YS9U2W3RQ</RegistryNumber><NameOfSubstance UI="C045345">gastrodin</NameOfSubstance></Chemical><Chemical><RegistryNumber>67763-96-6</RegistryNumber><NameOfSubstance UI="D007334">Insulin-Like Growth Factor I</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D000071679">Glycogen Synthase Kinase 3 beta</NameOfSubstance></Chemical><Chemical><RegistryNumber>SY7Q814VUP</RegistryNumber><NameOfSubstance UI="D002118">Calcium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001369" MajorTopicYN="N">Axons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001592" MajorTopicYN="N">Benzyl Alcohols</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005960" MajorTopicYN="N">Glucosides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018698" MajorTopicYN="N">Glutamic Acid</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071679" MajorTopicYN="N">Glycogen Synthase Kinase 3 beta</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057026" MajorTopicYN="N">Induced Pluripotent Stem Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007334" MajorTopicYN="N">Insulin-Like Growth Factor I</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020935" MajorTopicYN="N">MAP Kinase Signaling System</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009412" MajorTopicYN="N">Nerve Fibers</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016501" MajorTopicYN="N">Neurites</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">GSK3&#x3b2;</Keyword><Keyword MajorTopicYN="N">IGF-1</Keyword><Keyword MajorTopicYN="N">SOD1</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis (ALS)</Keyword><Keyword MajorTopicYN="N">drug screening</Keyword><Keyword MajorTopicYN="N">gastrodin</Keyword><Keyword MajorTopicYN="N">induced pluripotent stem cell (iPSC)</Keyword><Keyword MajorTopicYN="N">motor neuron (MN)</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>9</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>10</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>10</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>10</Month><Day>23</Day><Hour>1</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>10</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34685754</ArticleId><ArticleId IdType="pmc">PMC8535155</ArticleId><ArticleId IdType="doi">10.3390/cells10102773</ArticleId><ArticleId IdType="pii">cells10102773</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Robberecht W., Philips T. The changing scene of amyotrophic lateral sclerosis. Nat. Rev. Neurosci. 2013;14:248&#x2013;264. doi: 10.1038/nrn3430.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn3430</ArticleId><ArticleId IdType="pubmed">23463272</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith R., Pioro E., Myers K., Sirdofsky M., Goslin K., Meekins G., Yu H., Wymer J., Cudkowicz M., Macklin E.A., et al. Enhanced bulbar function in amyotrophic lateral sclerosis: The nuedexta treatment trial. Neurotherapeutics. 2017;14:762&#x2013;772. doi: 10.1007/s13311-016-0508-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-016-0508-5</ArticleId><ArticleId IdType="pmc">PMC5509619</ArticleId><ArticleId IdType="pubmed">28070747</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawada H. Clinical efficacy of edaravone for the treatment of amyotrophic lateral sclerosis. Expert Opin. Pharmacother. 2017;18:735&#x2013;738. doi: 10.1080/14656566.2017.1319937.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14656566.2017.1319937</ArticleId><ArticleId IdType="pubmed">28406335</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaiswal M.K. Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs. Med. Res. Rev. 2019;39:733&#x2013;748. doi: 10.1002/med.21528.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/med.21528</ArticleId><ArticleId IdType="pubmed">30101496</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng H.X., Hentati A., Tainer J.A., Iqbal Z., Cayabyab A., Hung W.Y., Getzoff E.D., Hu P., Herzfeldt B., Roos R.P., et al. Amyotrophic lateral sclerosis and structural defects in Cu, Zn superoxide dismutase. Science. 1993;261:1047&#x2013;1051. doi: 10.1126/science.8351519.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.8351519</ArticleId><ArticleId IdType="pubmed">8351519</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen D.R., Siddique T., Patterson D., Figlewicz D.A., Sapp P., Hentati A., Donaldson D., Goto J., O'Regan J.P., Deng H.-X., et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362:59&#x2013;62. doi: 10.1038/362059a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/362059a0</ArticleId><ArticleId IdType="pubmed">8446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadano S., Hand C.K., Osuga H., Yanagisawa Y., Otomo A., Devon R.S., Miyamoto N., Showguchi-Miyata J., Okada Y., Singaraja R., et al. A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2. Nat. Genet. 2001;29:166&#x2013;173. doi: 10.1038/ng1001-166.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng1001-166</ArticleId><ArticleId IdType="pubmed">11586298</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M., Sampathu D.M., Kwong L.K., Truax A.C., Micsenyi M.C., Chou T.T., Bruce J., Schuck T., Grossman M., Clark C.M., et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130&#x2013;133. doi: 10.1126/science.1134108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1134108</ArticleId><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T., Hasegawa M., Akiyama H., Ikeda K., Nonaka T., Mori H., Mann D., Tsuchiya K., Yoshida M., Hashizume Y., et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem. Biophys. Res. Commun. 2006;351:602&#x2013;611. doi: 10.1016/j.bbrc.2006.10.093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2006.10.093</ArticleId><ArticleId IdType="pubmed">17084815</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton A.E., Majounie E., Waite A., Simon-Sanchez J., Rollinson S., Gibbs J.R., Schymick J.C., Laaksovirta H., van Swieten J.C., Myllykangas L., et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72:257&#x2013;268. doi: 10.1016/j.neuron.2011.09.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.010</ArticleId><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwiatkowski T.J., Jr., Bosco D.A., Leclerc A.L., Tamrazian E., Vanderburg C.R., Russ C., Davis A., Gilchrist J., Kasarskis E.J., Munsat T., et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science. 2009;323:1205&#x2013;1208. doi: 10.1126/science.1166066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1166066</ArticleId><ArticleId IdType="pubmed">19251627</ArticleId></ArticleIdList></Reference><Reference><Citation>Vance C., Rogelj B., Hortobagyi T., De Vos K.J., Nishimura A.L., Sreedharan J., Hu X., Smith B., Ruddy D., Wright P., et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science. 2009;323:1208&#x2013;1211. doi: 10.1126/science.1165942.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1165942</ArticleId><ArticleId IdType="pmc">PMC4516382</ArticleId><ArticleId IdType="pubmed">19251628</ArticleId></ArticleIdList></Reference><Reference><Citation>Maruyama H., Morino H., Ito H., Izumi Y., Kato H., Watanabe Y., Kinoshita Y., Kamada M., Nodera H., Suzuki H., et al. Mutations of optineurin in amyotrophic lateral sclerosis. Nature. 2010;465:223&#x2013;226. doi: 10.1038/nature08971.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature08971</ArticleId><ArticleId IdType="pubmed">20428114</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuda H., Han S.M., Yang Y., Tong C., Lin Y.Q., Mohan K., Haueter C., Zoghbi A., Harati Y., Kwan J., et al. The amyotrophic lateral sclerosis 8 protein VAPB is cleaved, secreted, and acts as a ligand for Eph receptors. Cell. 2008;133:963&#x2013;977. doi: 10.1016/j.cell.2008.04.039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2008.04.039</ArticleId><ArticleId IdType="pmc">PMC2494862</ArticleId><ArticleId IdType="pubmed">18555774</ArticleId></ArticleIdList></Reference><Reference><Citation>Carpenter S. Proximal axonal enlargement in motor neuron disease. Neurology. 1968;18:841&#x2013;851. doi: 10.1212/WNL.18.9.841.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.18.9.841</ArticleId><ArticleId IdType="pubmed">4176657</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirano A., Nakano I., Kurland L.T., Mulder D.W., Holley P.W., Saccomanno G. Fine structural study of neurofibrillary changes in a family with amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol. 1984;43:471&#x2013;480. doi: 10.1097/00005072-198409000-00002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005072-198409000-00002</ArticleId><ArticleId IdType="pubmed">6540800</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith E.F., Shaw P.J., De Vos K.J. The role of mitochondria in amyotrophic lateral sclerosis. Neurosci. Lett. 2019;710:132933. doi: 10.1016/j.neulet.2017.06.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2017.06.052</ArticleId><ArticleId IdType="pubmed">28669745</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker A.K., Atkin J.D. Stress signaling from the endoplasmic reticulum: A central player in the pathogenesis of amyotrophic lateral sclerosis. IUBMB Life. 2011;63:754&#x2013;763. doi: 10.1002/iub.520.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/iub.520</ArticleId><ArticleId IdType="pubmed">21834058</ArticleId></ArticleIdList></Reference><Reference><Citation>Barber S.C., Mead R.J., Shaw P.J. Oxidative stress in ALS: A mechanism of neurodegeneration and a therapeutic target. Biochim. Biophys. Acta. 2006;1762:1051&#x2013;1067. doi: 10.1016/j.bbadis.2006.03.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2006.03.008</ArticleId><ArticleId IdType="pubmed">16713195</ArticleId></ArticleIdList></Reference><Reference><Citation>Lutz C. Mouse models of ALS: Past, present and future. Brain Res. 2018;1693:1&#x2013;10. doi: 10.1016/j.brainres.2018.03.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2018.03.024</ArticleId><ArticleId IdType="pubmed">29577886</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrice J.R., Gregory-Evans C.Y., Shaw C.A. Animal models of amyotrophic lateral sclerosis: A comparison of model validity. Neural Regen. Res. 2018;13:2050&#x2013;2054. doi: 10.4103/1673-5374.241445.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1673-5374.241445</ArticleId><ArticleId IdType="pmc">PMC6199948</ArticleId><ArticleId IdType="pubmed">30323119</ArticleId></ArticleIdList></Reference><Reference><Citation>Egawa N., Kitaoka S., Tsukita K., Naitoh M., Takahashi K., Yamamoto T., Adachi F., Kondo T., Okita K., Asaka I., et al. Drug screening for ALS using patient-specific induced pluripotent stem cells. Sci. Transl. Med. 2012;4:145ra104. doi: 10.1126/scitranslmed.3004052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3004052</ArticleId><ArticleId IdType="pubmed">22855461</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitne-Neto M., Machado-Costa M., Marchetto M.C., Bengtson M.H., Joazeiro C.A., Tsuda H., Bellen H.J., Silva H.C., Oliveira A.S., Lazar M., et al. Downregulation of VAPB expression in motor neurons derived from induced pluripotent stem cells of ALS8 patients. Hum. Mol. Genet. 2011;20:3642&#x2013;3652. doi: 10.1093/hmg/ddr284.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddr284</ArticleId><ArticleId IdType="pmc">PMC3159551</ArticleId><ArticleId IdType="pubmed">21685205</ArticleId></ArticleIdList></Reference><Reference><Citation>Alves C.J., Dariolli R., Jorge F.M., Monteiro M.R., Maximino J.R., Martins R.S., Strauss B.E., Krieger J.E., Callegaro D., Chadi G. Gene expression profiling for human iPS-derived motor neurons from sporadic ALS patients reveals a strong association between mitochondrial functions and neurodegeneration. Front. Cell. Neurosci. 2015;9:289. doi: 10.3389/fncel.2015.00289.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2015.00289</ArticleId><ArticleId IdType="pmc">PMC4523944</ArticleId><ArticleId IdType="pubmed">26300727</ArticleId></ArticleIdList></Reference><Reference><Citation>Ichiyanagi N., Fujimori K., Yano M., Ishihara-Fujisaki C., Sone T., Akiyama T., Okada Y., Akamatsu W., Matsumoto T., Ishikawa M., et al. Establishment of In Vitro FUS-Associated Familial Amyotrophic Lateral Sclerosis Model Using Human Induced Pluripotent Stem Cells. Stem Cell Reports. 2016;6:496&#x2013;510. doi: 10.1016/j.stemcr.2016.02.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2016.02.011</ArticleId><ArticleId IdType="pmc">PMC4834049</ArticleId><ArticleId IdType="pubmed">26997647</ArticleId></ArticleIdList></Reference><Reference><Citation>Imamura K., Izumi Y., Watanabe A., Tsukita K., Woltjen K., Yamamoto T., Hotta A., Kondo T., Kitaoka S., Ohta A., et al. The Src/c-Abl pathway is a potential therapeutic target in amyotrophic lateral sclerosis. Sci. Transl. Med. 2017;9:eaaf3962. doi: 10.1126/scitranslmed.aaf3962.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aaf3962</ArticleId><ArticleId IdType="pubmed">28539470</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H., Qian K., Du Z., Cao J., Petersen A., Liu H., Blackbourn L.W.t., Huang C.L., Errigo A., Yin Y., et al. Modeling ALS with iPSCs reveals that mutant SOD1 misregulates neurofilament balance in motor neurons. Cell Stem Cell. 2014;14:796&#x2013;809. doi: 10.1016/j.stem.2014.02.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2014.02.004</ArticleId><ArticleId IdType="pmc">PMC4230530</ArticleId><ArticleId IdType="pubmed">24704493</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiskinis E., Sandoe J., Williams L.A., Boulting G.L., Moccia R., Wainger B.J., Han S., Peng T., Thams S., Mikkilineni S., et al. Pathways disrupted in human ALS motor neurons identified through genetic correction of mutant SOD1. Cell Stem Cell. 2014;14:781&#x2013;795. doi: 10.1016/j.stem.2014.03.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2014.03.004</ArticleId><ArticleId IdType="pmc">PMC4653065</ArticleId><ArticleId IdType="pubmed">24704492</ArticleId></ArticleIdList></Reference><Reference><Citation>Burkhardt M.F., Martinez F.J., Wright S., Ramos C., Volfson D., Mason M., Garnes J., Dang V., Lievers J., Shoukat-Mumtaz U., et al. A cellular model for sporadic ALS using patient-derived induced pluripotent stem cells. Mol. Cell. Neurosci. 2013;56:355&#x2013;364. doi: 10.1016/j.mcn.2013.07.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2013.07.007</ArticleId><ArticleId IdType="pmc">PMC4772428</ArticleId><ArticleId IdType="pubmed">23891805</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K., Donnelly C.J., Haeusler A.R., Grima J.C., Machamer J.B., Steinwald P., Daley E.L., Miller S.J., Cunningham K.M., Vidensky S., et al. The C9orf72 repeat expansion disrupts nucleocytoplasmic transport. Nature. 2015;525:56&#x2013;61. doi: 10.1038/nature14973.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature14973</ArticleId><ArticleId IdType="pmc">PMC4800742</ArticleId><ArticleId IdType="pubmed">26308891</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo W., Naujock M., Fumagalli L., Vandoorne T., Baatsen P., Boon R., Ordovas L., Patel A., Welters M., Vanwelden T., et al. HDAC6 inhibition reverses axonal transport defects in motor neurons derived from FUS-ALS patients. Nat. Commun. 2017;8:1&#x2013;15. doi: 10.1038/s41467-017-00911-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-00911-y</ArticleId><ArticleId IdType="pmc">PMC5636840</ArticleId><ArticleId IdType="pubmed">29021520</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujimori K., Ishikawa M., Otomo A., Atsuta N., Nakamura R., Akiyama T., Hadano S., Aoki M., Saya H., Sobue G., et al. Modeling sporadic ALS in iPSC-derived motor neurons identifies a potential therapeutic agent. Nat. Med. 2018;24:1579&#x2013;1589. doi: 10.1038/s41591-018-0140-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-018-0140-5</ArticleId><ArticleId IdType="pubmed">30127392</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhinge A., Namboori S.C., Zhang X., VanDongen A.M.J., Stanton L.W. Genetic correction of SOD1 mutant iPSCs reveals ERK and JNK activated AP1 as a driver of neurodegeneration in amyotrophic lateral sclerosis. Stem Cell Rep. 2017;8:856&#x2013;869. doi: 10.1016/j.stemcr.2017.02.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2017.02.019</ArticleId><ArticleId IdType="pmc">PMC5390134</ArticleId><ArticleId IdType="pubmed">28366453</ArticleId></ArticleIdList></Reference><Reference><Citation>Macarthur C.C., Fontes A., Ravinder N., Kuninger D., Kaur J., Bailey M., Taliana A., Vemuri M.C., Lieu P.T. Generation of human-induced pluripotent stem cells by a nonintegrating RNA Sendai virus vector in feeder-free or xeno-free conditions. Stem Cells Int. 2012;2012:1&#x2013;9. doi: 10.1155/2012/564612.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2012/564612</ArticleId><ArticleId IdType="pmc">PMC3328201</ArticleId><ArticleId IdType="pubmed">22550511</ArticleId></ArticleIdList></Reference><Reference><Citation>Basso D.M., Beattie M.S., Bresnahan J.C. Graded histological and locomotor outcomes after spinal cord contusion using the NYU weight-drop device versus transection. Exp. Neurol. 1996;139:244&#x2013;256. doi: 10.1006/exnr.1996.0098.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/exnr.1996.0098</ArticleId><ArticleId IdType="pubmed">8654527</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruijn L.I., Becher M.W., Lee M.K., Anderson K.L., Jenkins N.A., Copeland N.G., Sisodia S.S., Rothstein J.D., Borchelt D.R., Price D.L., et al. ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron. 1997;18:327&#x2013;338. doi: 10.1016/S0896-6273(00)80272-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(00)80272-X</ArticleId><ArticleId IdType="pubmed">9052802</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao X., Antonyuk S.V., Seetharaman S.V., Whitson L.J., Taylor A.B., Holloway S.P., Strange R.W., Doucette P.A., Valentine J.S., Tiwari A., et al. Structures of the G85R variant of SOD1 in familial amyotrophic lateral sclerosis. J. Biol. Chem. 2008;283:16169&#x2013;16177. doi: 10.1074/jbc.M801522200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M801522200</ArticleId><ArticleId IdType="pmc">PMC2414278</ArticleId><ArticleId IdType="pubmed">18378676</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S.-M., Lee M.-S., Chang C.-Y., Lin S.-Z., Cheng E.-H., Liu Y.-H., Pan H.-C., Lee H.-C., Su H.-L. Prerequisite OCT4 maintenance potentiates the neural induction of differentiating human embryonic stem cells and induced pluripotent stem cells. Cell Transplant. 2015;24:829&#x2013;844. doi: 10.3727/096368913X675179.</Citation><ArticleIdList><ArticleId IdType="doi">10.3727/096368913X675179</ArticleId><ArticleId IdType="pubmed">24256943</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang C.-Y., Chen S.-M., Lu H.-E., Lai S.-M., Lai P.-S., Shen P.-W., Chen P.-Y., Shen C.-I., Harn H.-J., Lin S.-Z., et al. N-butylidenephthalide attenuates Alzheimer&#x2019;s disease-like cytopathy in Down syndrome induced pluripotent stem cell-derived neurons. Sci Rep. 2015;5:8744. doi: 10.1038/srep08744.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep08744</ArticleId><ArticleId IdType="pmc">PMC4348654</ArticleId><ArticleId IdType="pubmed">25735452</ArticleId></ArticleIdList></Reference><Reference><Citation>Maury Y., Come J., Piskorowski R.A., Salah-Mohellibi N., Chevaleyre V., Peschanski M., Martinat C., Nedelec S. Combinatorial analysis of developmental cues efficiently converts human pluripotent stem cells into multiple neuronal subtypes. Nat. Biotechnol. 2015;33:89&#x2013;96. doi: 10.1038/nbt.3049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.3049</ArticleId><ArticleId IdType="pubmed">25383599</ArticleId></ArticleIdList></Reference><Reference><Citation>Du F., Wang X., Shang B., Fang J., Xi Y., Li A., Diao Y. Gastrodin ameliorates spinal cord injury via antioxidant and anti-inflammatory effects. Acta Biochim. Pol. 2016;63:589&#x2013;593. doi: 10.18388/abp.2016_1272.</Citation><ArticleIdList><ArticleId IdType="doi">10.18388/abp.2016_1272</ArticleId><ArticleId IdType="pubmed">27474401</ArticleId></ArticleIdList></Reference><Reference><Citation>Bae J.S., Simon N.G., Menon P., Vucic S., Kiernan M.C. The puzzling case of hyperexcitability in amyotrophic lateral sclerosis. J. Clin. Neurol. 2013;9:65&#x2013;74. doi: 10.3988/jcn.2013.9.2.65.</Citation><ArticleIdList><ArticleId IdType="doi">10.3988/jcn.2013.9.2.65</ArticleId><ArticleId IdType="pmc">PMC3633193</ArticleId><ArticleId IdType="pubmed">23626643</ArticleId></ArticleIdList></Reference><Reference><Citation>Du Z.W., Chen H., Liu H., Lu J., Qian K., Huang C.L., Zhong X., Fan F., Zhang S.C. Generation and expansion of highly pure motor neuron progenitors from human pluripotent stem cells. Nat. Commun. 2015;6:1&#x2013;9. doi: 10.1038/ncomms7626.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms7626</ArticleId><ArticleId IdType="pmc">PMC4375778</ArticleId><ArticleId IdType="pubmed">25806427</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney M.E., Fleck T.J., Himes C.S., Hall E.D. Riluzole preserves motor function in a transgenic model of familial amyotrophic lateral sclerosis. Neurology. 1998;50:62&#x2013;66. doi: 10.1212/WNL.50.1.62.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.50.1.62</ArticleId><ArticleId IdType="pubmed">9443458</ArticleId></ArticleIdList></Reference><Reference><Citation>Hogg M.C., Halang L., Woods I., Coughlan K.S., Prehn J.H.M. Riluzole does not improve lifespan or motor function in three ALS mouse models. Amyotroph. Lateral Scler. Front. Degener. 2018;19:438&#x2013;445. doi: 10.1080/21678421.2017.1407796.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1407796</ArticleId><ArticleId IdType="pubmed">29221425</ArticleId></ArticleIdList></Reference><Reference><Citation>Warita H., Manabe Y., Murakami T., Shiro Y., Nagano I., Abe K. Early decrease of survival signal-related proteins in spinal motor neurons of presymptomatic transgenic mice with a mutant SOD1 gene. Apoptosis. 2001;6:345&#x2013;352. doi: 10.1023/A:1011334018804.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/A:1011334018804</ArticleId><ArticleId IdType="pubmed">11483858</ArticleId></ArticleIdList></Reference><Reference><Citation>Allodi I., Comley L., Nichterwitz S., Nizzardo M., Simone C., Benitez J.A., Cao M., Corti S., Hedlund E. Differential neuronal vulnerability identifies IGF-2 as a protective factor in ALS. Sci. Rep. 2016;6:25960. doi: 10.1038/srep25960.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep25960</ArticleId><ArticleId IdType="pmc">PMC4867585</ArticleId><ArticleId IdType="pubmed">27180807</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin J.H., Cho S.I., Lim H.R., Lee J.K., Lee Y.A., Noh J.S., Joo I.S., Kim K.W., Gwag B.J. Concurrent administration of Neu2000 and lithium produces marked improvement of motor neuron survival, motor function, and mortality in a mouse model of amyotrophic lateral sclerosis. Mol. Pharmacol. 2007;71:965&#x2013;975. doi: 10.1124/mol.106.030676.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/mol.106.030676</ArticleId><ArticleId IdType="pubmed">17105868</ArticleId></ArticleIdList></Reference><Reference><Citation>Sugai F., Yamamoto Y., Miyaguchi K., Zhou Z., Sumi H., Hamasaki T., Goto M., Sakoda S. Benefit of valproic acid in suppressing disease progression of ALS model mice. Eur. J. Neurosci. 2004;20:3179&#x2013;3183. doi: 10.1111/j.1460-9568.2004.03765.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1460-9568.2004.03765.x</ArticleId><ArticleId IdType="pubmed">15579172</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng H.-L., Leng Y., Ma C.-H., Zhang J., Ren M., Chuang D.-M. Combined lithium and valproate treatment delays disease onset, reduces neurological deficits and prolongs survival in an amyotrophic lateral sclerosis mouse model. Neuroscience. 2008;155:567&#x2013;572. doi: 10.1016/j.neuroscience.2008.06.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2008.06.040</ArticleId><ArticleId IdType="pmc">PMC2709275</ArticleId><ArticleId IdType="pubmed">18640245</ArticleId></ArticleIdList></Reference><Reference><Citation>Koh S.-H., Kim Y., Kim H.Y., Hwang S., Lee C.H., Kim S.H. Inhibition of glycogen synthase kinase-3 suppresses the onset of symptoms and disease progression of G93A-SOD1 mouse model of ALS. Exp. Neurol. 2007;205:336&#x2013;346. doi: 10.1016/j.expneurol.2007.03.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2007.03.004</ArticleId><ArticleId IdType="pubmed">17433298</ArticleId></ArticleIdList></Reference><Reference><Citation>Li B., Xu W., Luo C., Gozal D., Liu R. VEGF-induced activation of the PI3-K/Akt pathway reduces mutant SOD1-mediated motor neuron cell death. Brain Res. Mol. Brain Res. 2003;111:155&#x2013;164. doi: 10.1016/S0169-328X(03)00025-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0169-328X(03)00025-1</ArticleId><ArticleId IdType="pubmed">12654515</ArticleId></ArticleIdList></Reference><Reference><Citation>Group U.K.-L.S., Morrison K.E., Dhariwal S., Hornabrook R., Savage L., Burn D.J., Khoo T.K., Kelly J., Murphy C.L., Al-Chalabi A., et al. Lithium in patients with amyotrophic lateral sclerosis (LiCALS): A phase 3 multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2013;12:339&#x2013;345. doi: 10.1016/S1474-4422(13)70037-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(13)70037-1</ArticleId><ArticleId IdType="pmc">PMC3610091</ArticleId><ArticleId IdType="pubmed">23453347</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez-Fernandez C., Gonzalez P., Andres-Benito P., Ferrer I., Rodriguez F.J. Wnt signaling alterations in the human spinal cord of amyotrophic lateral sclerosis cases: Spotlight on Fz2 and Wnt5a. Mol. Neurobiol. 2019;56:6777&#x2013;6791. doi: 10.1007/s12035-019-1547-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-019-1547-9</ArticleId><ArticleId IdType="pubmed">30924074</ArticleId></ArticleIdList></Reference><Reference><Citation>Vohnoutka R.B., Boumil E.F., Liu Y., Uchida A., Pant H.C., Shea T.B. Influence of a GSK3beta phosphorylation site within the proximal C-terminus of Neurofilament-H on neurofilament dynamics. Biol. Open. 2017;6:1516&#x2013;1527. doi: 10.1242/bio.028522.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/bio.028522</ArticleId><ArticleId IdType="pmc">PMC5665472</ArticleId><ArticleId IdType="pubmed">28882840</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S., Pant H.C., Shea T.B. Divergent and convergent roles for kinases and phosphatases in neurofilament dynamics. J. Cell Sci. 2014;127:4064&#x2013;4077. doi: 10.1242/jcs.153346.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.153346</ArticleId><ArticleId IdType="pmc">PMC6519427</ArticleId><ArticleId IdType="pubmed">25015294</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin L.-C., Chen Y.-F., Lee W.-C., Wu Y.-T., Tsai T.-H. Pharmacokinetics of gastrodin and its metabolite p-hydroxybenzyl alcohol in rat blood, brain and bile by microdialysis coupled to LC-MS/MS. J. Pharm. Biomed. Anal. 2008;48:909&#x2013;917. doi: 10.1016/j.jpba.2008.07.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpba.2008.07.013</ArticleId><ArticleId IdType="pubmed">18757149</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>